ValCare Medical
Minimally Invasive Treatment for Valve Disease
Company Overview
Snapshot
Founded in June 2012 by Samuel Shaolian, ValCare Medical operates with 11–50 employees. The company has raised $23 million across three funding rounds from four investors. In April 2024, ValCare Medical announced a corporate restructuring and the appointment of a new CEO.
Business overview
ValCare Medical is a Health Tech & Life Sciences company focused on developing innovative minimally-invasive technologies for the treatment of mitral and tricuspid regurgitation. Its product line includes solutions for the repair and replacement of the mitral valve and repair of the tricuspid valve, with a breakthrough mitral valve treatment platform based on a D-shaped ring for annulus repair and as a docking station for its exclusive replacement prosthesis. The company serves the cardiology and medical device sectors, targeting surgeons and hospitals globally.
Strategic signal
In May 2024, ValCare Medical announced the enrollment of the first two patients in its AMEND™ TS EU Pilot Study. This milestone indicates significant progress in the clinical development and validation of its transseptal annuloplasty ring, signaling potential for future market expansion and regulatory approvals for its minimally invasive valve repair solutions.
Log in to access full profile ›Company Intelligence Q&A
- What is ValCare Medical's core focus?
- ValCare Medical is dedicated to providing innovative minimally-invasive technologies for the treatment of mitral and tricuspid regurgitation, focusing on solutions for valve repair and replacement.
- When did ValCare Medical announce a corporate restructuring and new CEO?
- In April 2024, ValCare Medical announced a corporate restructuring and the appointment of a new CEO.
- What was a key development for the AMEND™ TS EU Pilot Study?
- In May 2024, ValCare Medical announced the enrollment of the first two patients in its AMEND™ TS EU Pilot Study.
- When did ValCare Medical announce its first-in-human transseptal implant of the AMEND™ Annuloplasty Ring?
- In January 2021, ValCare Medical announced the first-in-human transseptal implant of the AMEND™ Annuloplasty Ring for mitral valve repair.
- Which investors participated in ValCare Medical's September 2018 funding round?
- In September 2018, ValCare Medical received funding from investors including Accelmed.